Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(d) Election of Director
On January 29, 2020, the Board of Directors (the "Board") of Synlogic, Inc. (the
"Company"), following the recommendation of the Nominating and Corporate
Governance Committee of the Board, appointed Michael F. Burgess, M.B., Ch.B.,
Ph.D., effective February 3, 2020 (the "Effective Date"), as a director to the
Board to serve as a Class III Director with a term expiring at the Company's
2021 annual meeting of stockholders.
Dr. Michael Burgess has been President of Research and Development at Turnstone
Biologics since 2017. Prior to joining Turnstone Biologics, Dr. Burgess worked
at Bristol-Myers Squibb where he led strategy and execution of translational
medicine, early-stage clinical trials and clinical pharmacology across all
therapeutic areas. Prior to his work at Bristol-Myers Squibb, Dr. Burgess held
several senior leadership positions at Roche Pharmaceuticals, including acting
Global Head of Roche Pharma Research and Early Development (pRED) and Senior
Vice President and Global Head of Oncology Research and Early Development.
Before joining Roche Pharmaceuticals, Dr. Burgess worked on early stage oncology
clinical trials at Lilly and Company. He received his medical degree (M.B.,
Ch.B.) and a Ph.D. in molecular biology from the University of Bristol, U.K. and
spent 10 years as a practicing physician in pediatrics and pediatric oncology.
In connection with Dr. Burgess' election to the Board, and pursuant to the
Company's Amended and Restated Non-Employee Director Compensation Program (as
amended as described in Item 5.02(e) below) (the "Director Compensation
Program"), on the Effective Date, Dr. Burgess will be granted a stock option to
purchase 30,000 shares of the Company's common stock. The stock option will have
an exercise price per share equal to the closing price of the Company's common
stock on The Nasdaq Capital Market on the date of grant. The stock option will
vest in substantially equal installments on each of the first three
anniversaries of the date of grant, subject to Dr. Burgess' continued service as
a director.
In addition, Dr. Burgess is entitled to receive an annual cash retainer of
$40,000 for his service as a non-employee director of the Company pursuant to
the Director Compensation Program, prorated for the portion of the year that
Dr. Burgess serves as a director.
Also in connection with Dr. Burgess' election to the Board, Dr. Burgess and the
Company will enter into an indemnification agreement in the form the Company has
entered into with its other non-employee directors, which form is filed as
Exhibit 10.13 to the Company's Amendment No. 1 to its Registration Statement on
Form S-1 (File No. 333-206544) filed by the Company on September 11, 2015. Under
this agreement, the Company will agree, among other things, to indemnify
Dr. Burgess for certain expenses, including attorneys' fees, judgments, fines
and settlement amounts incurred by him in any action or proceeding arising out
of his service as one of the Company's directors.
There are no arrangements or understandings between Dr. Burgess and any other
person pursuant to which Dr. Burgess was appointed as a director. There are no
transactions to which the Company is a party and in which Dr. Burgess has a
material interest that are required to be disclosed under Item 404(a) of
Regulation S-K. Dr. Burgess has not previously held any positions with the
Company and has no family relations with any directors or executive officers of
the Company.
On January 30, 2020, the Company issued a press release announcing Dr. Burgess'
appointment to the Board, a copy of which is attached to this Current Report on
Form 8-K as Exhibit 99.1.
(e) Compensatory Arrangement
On December 19, 2019, the Board, following the recommendation of the
Compensation Committee, approved an amendment to the Director Compensation
Policy, effective January 1, 2020. Pursuant to the Director Compensation Policy,
as amended, the Company's non-employee directors are entitled to receive
compensation in the following amounts, which may be paid in cash quarterly or,
at the election of the director, in the form of an option equal to the
Black-Scholes value of the annual retainer, which option will be granted on the
first business day of the calendar year and will vest in four quarterly
installments on the last day of each calendar quarter during the calendar year,
subject to continued service through each applicable vesting date:
• Each non-employee director receives an annual retainer in the amount of
$40,000 per year.
--------------------------------------------------------------------------------
• A non-employee director serving as Chairman of the Board receives an
additional annual retainer in the amount of $30,000 per year.
• A non-employee director serving as chairperson of the Audit Committee
receives an additional annual retainer of $15,000 for such service. A
non-employee director serving as a member of the Audit Committee (other
than the chairperson) receives an additional annual retainer of $7,500
for such service.
• A non-employee director serving as chairperson of the Compensation
Committee receives an additional annual retainer of $12,000 for such
service. A non-employee director serving as a member of the Compensation
Committee (other than the chairperson) receives an additional annual
retainer of $5,000 for such service.
• A non-employee director serving as chairperson of the Nominating and
Corporate Governance Committee receives an additional annual retainer of
$8,000 for such service. A non-employee director serving as a member of
the Nominating and Corporate Governance Committee (other than the
chairperson) receives an additional annual retainer of $4,000 for such
service.
Under the Director Compensation Program, upon a director's initial appointment
or election to the Board, the non-employee director will receive an option to
purchase 30,000 shares of common stock (subject to adjustment as provided in the
applicable equity plan) (the "Initial Grant"). In addition, each non-employee
director who has been serving as a director for at least three months prior to
any annual stockholder meeting and will continue to serve as a director
immediately following such annual stockholder meeting will be automatically
granted, on the date of such annual stockholder meeting, an option to purchase
15,000 shares of common stock (subject to adjustment as provided in the
applicable equity plan) (the "Annual Grant"). The Initial Grant will vest in
substantially equal installments on each of the first three anniversaries of the
applicable grant date, subject to continued service through each applicable
vesting date, and the Annual Grant will vest in full on the earlier of the first
anniversary of the applicable grant date or immediately prior to the next annual
stockholder meeting after the applicable grant date, subject to continued
service through such vesting date. In addition, pursuant to the terms of the
Director Compensation Program, all equity awards outstanding and held by a
non-employee director will vest in full immediately prior to the occurrence of a
change in control.
The foregoing summary of the Director Compensation Program does not purport to
be complete and is qualified in its entirety by reference to such policy, a copy
of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated by reference in this Item 5.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
10.1# Non-Employee Director Compensation Program
99.1 Press Release dated January 30, 2020.
# Management contract or compensatory plan or arrangement.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses